Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more
Abbott Laboratories (ABT) - Total Assets
Latest total assets as of September 2025: $84.18 Billion USD
Based on the latest financial reports, Abbott Laboratories (ABT) holds total assets worth $84.18 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abbott Laboratories - Total Assets Trend (1985–2024)
This chart illustrates how Abbott Laboratories’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abbott Laboratories - Asset Composition Analysis
Current Asset Composition (December 2024)
Abbott Laboratories's total assets of $84.18 Billion consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $7.62 Billion | 9.4% |
| Accounts Receivable | $6.92 Billion | 8.5% |
| Inventory | $6.19 Billion | 7.6% |
| Property, Plant & Equipment | $11.73 Billion | 14.4% |
| Intangible Assets | $6.65 Billion | 8.2% |
| Goodwill | $23.11 Billion | 28.4% |
Asset Composition Trend (1985–2024)
This chart illustrates how Abbott Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abbott Laboratories's current assets represent 29.1% of total assets in 2024, a decrease from 48.5% in 1985.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 12.6% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 36.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 28.4% of total assets.
Abbott Laboratories Competitors by Total Assets
Key competitors of Abbott Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Abbott Laboratories - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Abbott Laboratories generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Abbott Laboratories generates $ 16.46 in net profit.
Abbott Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 1.60 | 1.72 |
| Quick Ratio | 1.24 | 1.14 | 1.30 |
| Cash Ratio | 0.52 | 0.51 | 0.00 |
| Working Capital | $10.26 Billion | $ 8.90 Billion | $ 8.53 Billion |
Abbott Laboratories - Advanced Valuation Insights
This section examines the relationship between Abbott Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.85 |
| Latest Market Cap to Assets Ratio | 2.35 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | $81.41 Billion |
| Market Capitalization | $191.37 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abbott Laboratories's assets at a significant premium ( 2.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Abbott Laboratories's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abbott Laboratories (1985–2024)
The table below shows the annual total assets of Abbott Laboratories from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $81.41 Billion | +11.20% |
| 2023-12-31 | $73.21 Billion | -1.64% |
| 2022-12-31 | $74.44 Billion | -1.01% |
| 2021-12-31 | $75.20 Billion | +3.65% |
| 2020-12-31 | $72.55 Billion | +6.87% |
| 2019-12-31 | $67.89 Billion | +1.06% |
| 2018-12-31 | $67.17 Billion | -11.90% |
| 2017-12-31 | $76.25 Billion | +38.61% |
| 2016-12-31 | $55.01 Billion | +25.02% |
| 2015-12-31 | $44.00 Billion | +0.48% |
| 2014-12-31 | $43.79 Billion | +1.95% |
| 2013-12-31 | $42.95 Billion | -36.12% |
| 2012-12-31 | $67.23 Billion | +11.54% |
| 2011-12-31 | $60.28 Billion | -0.49% |
| 2010-12-31 | $60.57 Billion | +15.20% |
| 2009-12-31 | $52.58 Billion | +23.96% |
| 2008-12-31 | $42.42 Billion | +6.81% |
| 2007-12-31 | $39.71 Billion | +9.77% |
| 2006-12-31 | $36.18 Billion | +24.15% |
| 2005-12-31 | $29.14 Billion | +1.30% |
| 2004-12-31 | $28.77 Billion | +7.68% |
| 2003-12-31 | $26.72 Billion | +10.13% |
| 2002-12-31 | $24.26 Billion | +4.13% |
| 2001-12-31 | $23.30 Billion | +52.43% |
| 2000-12-31 | $15.28 Billion | +5.61% |
| 1999-12-31 | $14.47 Billion | +9.49% |
| 1998-12-31 | $13.22 Billion | +9.58% |
| 1997-12-31 | $12.06 Billion | +8.41% |
| 1996-12-31 | $11.13 Billion | +18.20% |
| 1995-12-31 | $9.41 Billion | +10.43% |
| 1994-12-31 | $8.52 Billion | +10.86% |
| 1993-12-31 | $7.69 Billion | +10.77% |
| 1992-12-31 | $6.94 Billion | +10.97% |
| 1991-12-31 | $6.26 Billion | +12.44% |
| 1990-12-31 | $5.56 Billion | +14.67% |
| 1989-12-31 | $4.85 Billion | +0.55% |
| 1988-12-31 | $4.83 Billion | +10.02% |
| 1987-12-31 | $4.39 Billion | +13.45% |
| 1986-12-31 | $3.87 Billion | +11.45% |
| 1985-12-31 | $3.47 Billion | -- |